Migraine with brainstem aura market is expected to grow USD 10.67 Billion at a CAGR 5.30% the forecast period 2023 to 2030. A migraine with brainstem aura is also known as a basilar migraine or basilar artery migraine. It is a rare type of a migraine that begins in the base of the brain (brain stem). A migraine with brainstem aura occurs in about 1.5% of the patients suffering from with a headache. This migraine can occur in men and women of all ages.
The symptoms of this migraine include visual disturbances in both eyes, vertigo, hearing problems, nausea, dizziness among others. A migraine with brainstem aura (MBA) may affect one or both the sides of the brain. This rare migraine may be caused by a constriction of blood vessels that limit the blood flow to the brain. Moreover, certain external factors such as stress, motion sickness, epilepsy, alcoholism, prolonged hunger, excessive use of headache medications can trigger basilar artery migraines.
The factors such as rising prevalence of a migraine and growing awareness about rare types of migraines in the developed economies are major drivers for the market growth. In addition, the rising need for better treatment approaches, increasing investment of biotechnology and pharmaceutical industries in research & development (R&D) are expected to contribute to the growth of the market. However, side effects associated with migraine treatment drugs may hamper the growth of the market during the forecast period.
Segmentation
The migraine with brainstem aura market has been segmented into diagnosis, treatment, distribution channel, and end-user.
The market, by diagnosis, has been segmented into magnetic resonance imaging (MRI), computerized tomography (CT), and others.
The market, on the basis of treatment, has been segmented into abortive medication and preventive medication. The abortive medication segment has been segmented into non-steroidal anti-inflammatory drugs (NSAIDs), anti-nausea medications, and others. The preventive medication segment has been further segmented into botox injections, antidepressants, and others.
On the basis of the distribution channel, the market has been segmented into retail pharmacies, hospital pharmacies, and others.
The market, by end-user, has been segmented into hospital & clinics, diagnostic centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The migraine with brainstem aura market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European migraine with brainstem aura market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The migraine with brainstem aura market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The migraine with brainstem aura market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key players
Allergen Plc, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, AstraZeneca, Eisai Co., Ltd., Endo International Plc, Impax Laboratories, Eli Lily and Company, and Johnson & Johnson are some of the key players in the global market.
Regional Market Summary
Migraine with Brainstem Aura Market Share (%), by Region, 2017
Source: Centers for Disease Control and Prevention (CDC), White Papers, Company Presentations, Annual Reports
Geographically, the Americas is anticipated to dominate the migraine with brainstem aura market owing to a well-developed healthcare sector, rising prevalence of migraine and growing healthcare expenditure. According to the Centers for Disease Control and Prevention (CDC), in 2015, 20% of women and 9.7% of men aged 18 or more had a migraine. Additionally, the large number of research and development (R&D) activities contributes to the growth of the market.
Europe is expected to hold the second largest position in the migraine with brainstem aura. The market growth in this region is attributed to the availability of funds for research, growing prevalence of migraine, and increasing healthcare expenditure. According to the World Health Organization (WHO), it is estimated that around 1 in 7 people in the UK experience migraine. It also stated that there are around 190,000 migraine attacks in the UK.
The migraine with brainstem aura market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to continuously developing economies, rising prevalence of migraine and increasing government funding for the healthcare sector.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Migraine with Brainstem Aura Market, by Diagnosis
Migraine with Brainstem Aura Market, by Treatment
Migraine with Brainstem Aura Market, by Distribution Channel
Migraine with Brainstem Aura Market, by End-User
Migraine with Brainstem Aura Market, by Region
| Report Attribute/Metric | Details |
| Market Size | USD10.67 Billion |
| CAGR | 5.30% |
| Base Year | 2022 |
| Forecast Period | 2023-2030 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment, Diagnosis, Distribution Channel, End Users |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Allergen Plc, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, AstraZeneca, Eisai Co., Ltd., Endo International Plc, Impax Laboratories, Eli Lily and Company, and Johnson & Johnson are some of the key players in the global market. |
| Key Market Opportunities | |
| Key Market Drivers | Increasing investment of biotechnology and pharmaceutical industries in research & development |
Migraine Brainstem Aura Market Highlights:
Frequently Asked Questions (FAQ) :
Growing awareness regarding migraine would be the dominating factor for Migraine with Brainstem Aura Market growth.
Name segments related to a diagnosis that is a part of the Migraine with Brainstem Aura Market assessment. The segments of Migraine with Brainstem Aura Market are magnetic resonance imaging (MRI), computerized tomography (CT), and others.
Migraine with Brainstem Aura Market study includes abortive medication and preventive medication.
The study of Migraine with Brainstem Aura Market includes retail pharmacies, hospital pharmacies, and others.
The Americas would dominate global Migraine with Brainstem Aura Market study.
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
